Arash Pezhouman

Arash Pezhouman

Auto-generated profile, based on publicly available information

Arash Pezhouman

Cardiovascular Research Laboratory, UCLA, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PQPearl Quijada
Pearl Quijada
SPShuin Park
Shuin Park
PZPeng Zhao
Peng Zhao
KKKamal S.S. Kolluri
Kamal S.S. Kolluri
DWDavid Wong
David Wong
Reza ArdehaliReza Ardehali
Reza Ardehali
Despite the prevalence of pericytes in the microvasculature of the heart, their role during ischemia-induced remodeling remains unclear. We used multiple lineage-tracing mouse models and found that pericytes migrated to the injury site and expressed profibrotic genes, coinciding with increased vessel leakage after myocardial infarction (MI). Single-cell RNA-Seq of cardiac pericytes at various time points after MI revealed the temporally regulated induction of genes related to vascular permeability, extracellular matrix production, basement membrane degradation, and TGF-β signaling. Deleting TGF-β receptor 1 in chondroitin sulfate proteoglycan 4–expressing (Cspg4-expressing) cells reduced fibrosis following MI, leading to a transient improvement in the cardiac ejection fraction. Furthermore, genetic ablation of Cspg4-expressing cells resulted in excessive vascular permeability, a decline in cardiac function, and increased mortality in the second week after MI. These data reveal an essential role for cardiac pericytes in the control of vascular homeostasis and the fibrotic response after acute ischemic injury, information that will help guide the development of novel strategies to preserve vascular integrity and attenuate pathological cardiac remodeling.

6 February 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HKHrayr S. Karagueuzian
Hrayr S. Karagueuzian
APArash Pezhouman
Arash Pezhouman
MAMarina Angelini
Marina Angelini
RORiccardo Olcese
Riccardo Olcese
While recent advances clarified the molecular and cellular modes of action of antiarrhythmic drugs (AADs), their link to suppression of dynamical arrhythmia mechanisms remains only partially understood. The current classifications of AADs (Classes 1, III, and IV) rely on blocking peak Na, K and L-type calcium currents (ICa,L), with Class II with dominant beta receptor blocking activity and Class V including drugs with diverse classes of actions. The discovery that the calcium and redox sensor, cardiac Ca/calmodulin-dependent protein kinase II (CaMKII) enhances both the late Na (INa-L) and the late ICa-L in patients at high risk of VT/VF provided a new and a rational AAD target. Pathological rise of either or both of INa-L and late ICa,L are demonstrated to promote cellular early afterdepolarizations (EADs) and EAD-mediated triggered activity that initiates VT/VF in remodeled hearts. Selective inhibition of the INa-L without affecting their peak transients with the highly specific prototype drug, GS-96 suppresses these EAD-mediated VT/VFs. As in the case of INa-L, selective inhibition of the late ICa,L without affecting its peak with the prototype drug, roscovitine suppressed oxidative EAD-mediated VT/VF. These findings indicate that specific blockers of the late inward currents without affecting their peaks (gating modifiers), offer a new and effective AAD class action i.e., “Class VI.” The development of safe drugs with selective Class VI actions provides a rational and effective approach to treat VT/VF particularly in cardiac conditions associated with enhanced CaMKII activity such as heart failure.

26 October 2021 in Journal of General Physiology
Verified
Journal Article
Open access
PDF file
MAMarina Angelini
Marina Angelini
APArash Pezhouman
Arash Pezhouman
NSNicoletta Savalli
Nicoletta Savalli
MCMarvin G. Chang
Marvin G. Chang
FSFederica Steccanella
Federica Steccanella
RORiccardo Olcese
Riccardo Olcese
Ventricular arrhythmias, a leading cause of sudden cardiac death, can be triggered by cardiomyocyte early afterdepolarizations (EADs). EADs can result from an abnormal late activation of L-type Ca2+ channels (LTCCs). Current LTCC blockers (class IV antiarrhythmics), while effective at suppressing EADs, block both early and late components of ICa,L, compromising inotropy. However, computational studies have recently demonstrated that selective reduction of late ICa,L (Ca2+ influx during late phases of the action potential) is sufficient to potently suppress EADs, suggesting that effective antiarrhythmic action can be achieved without blocking the early peak ICa,L, which is essential for proper excitation–contraction coupling. We tested this new strategy using a purine analogue, roscovitine, which reduces late ICa,L with minimal effect on peak current. Scaling our investigation from a human CaV1.2 channel clone to rabbit ventricular myocytes and rat and rabbit perfused hearts, we demonstrate that (1) roscovitine selectively reduces ICa,L noninactivating component in a human CaV1.2 channel clone and in ventricular myocytes native current, (2) the pharmacological reduction of late ICa,L suppresses EADs and EATs (early after Ca2+ transients) induced by oxidative stress and hypokalemia in isolated myocytes, largely preserving cell shortening and normal Ca2+ transient, and (3) late ICa,L reduction prevents/suppresses ventricular tachycardia/fibrillation in ex vivo rabbit and rat hearts subjected to hypokalemia and/or oxidative stress. These results support the value of an antiarrhythmic strategy based on the selective reduction of late ICa,L to suppress EAD-mediated arrhythmias. Antiarrhythmic therapies based on this idea would modify the gating properties of CaV1.2 channels rather than blocking their pore, largely preserving contractility.

21 March 2021 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
APArash Pezhouman
Arash Pezhouman
JEJames L Engel
James L Engel
NNNgoc B Nguyen
Ngoc B Nguyen
RSRhys J P Skelton
Rhys J P Skelton
WGWilliam Blake Gilmore
William Blake Gilmore
Reza ArdehaliReza Ardehali
Reza Ardehali
Aims: We prospectively isolate and characterize first and second heart field- and nodal-like cardiomyocytes using a double reporter line from human embryonic stem cells. Our double reporter line utilizes two important transcription factors in cardiac development, TBX5 and NKX2-5. TBX5 expression marks first heart field progenitors and cardiomyocytes while NKX2-5 is expressed in nearly all myocytes of the developing heart (excluding nodal cells). We address the shortcomings of prior work in the generation of heart field-specific cardiomyocytes from induced pluripotent stem cells and provide a comprehensive early developmental transcriptomic as well as electrophysiological analyses of these three populations.Methods and results: Transcriptional, immunocytochemical, and functional studies support the cellular identities of isolated populations based on the expression pattern of NKX2-5 and TBX5. Importantly, bulk and single-cell RNA sequencing analyses provide evidence of unique molecular signatures of isolated first and second heart field cardiomyocytes, as well as nodal-like cells. Extensive electrophysiological analyses reveal dominant atrial action potential phenotypes in first and second heart fields in alignment with our findings in single-cell RNA sequencing. Lastly, we identify two novel surface markers, POPDC2 and CORIN, that enable purification of cardiomyocytes and first heart field cardiomyocytes, respectively.Conclusions: We describe a high-yield approach for isolation and characterization of human embryonic stem cell-derived heart field-specific and nodal-like cardiomyocytes. Obtaining enriched populations of these different cardiomyocyte subtypes increases the resolution of gene expression profiling during early cardiogenesis, arrhythmia modelling, and drug screening. This paves the way for the development of effective stem cell therapy to treat diseases that affect specific regions of the heart- or chamber-specific congenital heart defects.

17 October 2023 in Circulation
Verified
Journal Article
Closed access
JHJijun Huang
Jijun Huang
JLJosh Z. Lee
Josh Z. Lee
CRChristoph D. Rau
Christoph D. Rau
APArash Pezhouman
Arash Pezhouman
TYTomohiro Yokota
Tomohiro Yokota
YWYibin Wang
Yibin Wang

1 February 2016 in Biophysical Journal
Verified
Journal Article
Open access
PDF file
MAMarina Angelini
Marina Angelini
APArash Pezhouman
Arash Pezhouman
NSNicoletta Savalli
Nicoletta Savalli
APAntonios Pantazis
Antonios Pantazis
AMAraz Melkonian
Araz Melkonian
RORiccardo Olcese
Riccardo Olcese
L-type calcium current (ICa,L) plays a central role in counterbalancing potassium current during the plateau phase of cardiac action potential (AP). When repolarization reserve is reduced, the aberrant reactivation of ICa,L during repolarization can cause transient depolarization events called Early Afterdepolarizations (EADs), a recognized trigger of cardiac arrhythmias. Recently we demonstrated that EADs are highly sensitive to the steady-state voltage-dependent properties of ICa,L. Using the dynamic clamp technique in isolated rabbit ventricular myocytes under EAD-favoring condition (i.e. oxidative stress or hypokalemia), we found that selectively inhibiting the non-inactivating component (late) of ICa,L potently suppressed EAD-occurrence. Roscovitine, a purine analog, has been shown to reduce the late ICa,L component while leaving peak unperturbed. Here we tested the ability of this drug to suppress EADs in isolated rabbit ventricular myocytes induced by exposure to H2O2 (600µM). This oxidative stress caused EADs in 81% [95% CI: 66-95%] of the APs, prolonging AP duration (APD90) from 276 ms [97-433 ms] to 840ms [285-1967ms] (n=4). Addition of roscovitine (20µM) completely abolished EADs and reduced the APD90 to 189 ms [155-222 ms]. Moreover, roscovitine did not significantly perturb the Ca transient, implying maintenance of normal excitation-contraction coupling. We next exposed isolated aged rat hearts to 0.1 mM H2O2 to induce EADs and spontaneous ventricular tachycardia/fibrillation (VT/VF). In all tested hearts (n=4), roscovitine terminated VT/VF and led to resumption of sinus rhythm within 10 min. Our study offers additional proof of concept supporting a pharmacological strategy to target late ICa,L to prevent EAD-mediated arrhythmias, with roscovitine as an archetypal drug to guide the development of this new class of antiarrhythmics.